We’re excited to announce that for a second time in a row, based on positive survey results from our employees, we have been awarded a “World-class Workplace” for 2024-2025 by Effectory! We are grateful for everyone that makes Merus as a great place to work! #CloseInOnCancer
Merus N.V.
Biotechnologisch onderzoek
Utrecht, Utrecht 11.247 volgers
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c
Over ons
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/
- Website
-
http://www.merus.nl
Externe link voor Merus N.V.
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 201 - 500 medewerkers
- Hoofdkantoor
- Utrecht, Utrecht
- Type
- Naamloze vennootschap
- Specialismen
- immuno-oncology, oncology, immunology, antibody engineering, antibody discovery, cell biology, In vivo, biomarker development, early discovery, protein production, robotics en functional assays
Locaties
-
Primair
Yalelaan 62
Utrecht, Utrecht 3584 CM, NL
-
1 Broadway
Cambridge, MA 02142, US
Medewerkers van Merus N.V.
Updates
-
We’re excited to announce that the first patient has been dosed in LiGeR-HN2, a phase 3 trial evaluating petosemtamab in 2/3L r/m #HNSCC #CloseInOnCancer https://lnkd.in/gKEipjHp
-
-
Check out Benjamin’s story and learn how Merus is a place where he can focus on helping give patients a better quality of life. It’s an environment where curiosity and eagerness to innovate are very strong. Read more>> https://lnkd.in/eHh2WK7F #CloseInOnCancer #JoinTheMerusMission
-
-
Join us at the forefront of innovation. The stakes are high, and so are our ambitions. There is exciting work to be done with colleagues worldwide. Envision being part of our mission to #CloseInOnCancer by checking our open positions. https://careers.merus.nl/ #JoinTheMerusMission
-
-
NRG1 gene fusions have been identified across many tumor types and generally occur in the absence of other driver mutations. Learn more at https://bit.ly/45NptDs. #PrecisionOncology #FindTheFusions #PrecisionMedicine
-
-
Our team members are the heart and soul of Merus. We’ve invited our colleagues to share what makes Merus a great place to work. We’re kicking off our series with Maaike, our Associate Director Quality Systems. #CloseInOnCancer #JoinTheMerusMission Read more>> https://lnkd.in/eNz3svzA
-
-
Every day, we’re moving ahead in our mission to #CloseInOnCancer. We’re up to the challenge and unwavering in our determination. In the coming weeks, we’ll introduce you to some of our team members, who’ll share what motivates them and sparks their passion to make a difference. https://merus.nl/
-
-
At Merus, we work towards discovering and developing new treatments for cancer. Every day, we bring a sense of urgency and a passion to help patients with #HNSCC, #NSCLC, #PDAC, and other types of cancer. Time is of the essence. #CloseInOnCancer https://merus.nl/
-
-
Merus announces first patient dosed in phase 2 trial of petosemtamab in 2L CRC. #CloseInOnCancer https://lnkd.in/eNzJp6Dc
-
-
Welcoming Dr. Fabian Zohren as our new Chief Medical Officer. Bringing late-stage clinical development expertise to our team, Dr. Zohren will play a key role in the initiation of our two randomized phase 3 trials, planned to start later this year. #CloseInOnCancer
Vergelijkbare pagina’s
Door vacatures bladeren
Financiering
Laatste ronde
Vermogen na beursgangUS$ 400.200.000,00